Thank you for your interest in xenotransplantation through Mass General Transplant Center. Currently, Mass General has received FDA approval for a single-patient, compassionate use, xenotransplant trial involving a porcine gene-edited kidney transplant, successfully completed on March 16th, 2024. Mr. Slayman, the living kidney recipient, will be continuously monitored by our physician-scientists, with outcomes reported to the FDA. These outcomes will determine potential future trials.

If you or your patient are considering participation in future xenotransplant clinical trials upon FDA approval, please complete this questionnaire to the best of your knowledge. Completing this e-questionnaire and providing contact details, including email addresses, will help in future recruitment and eligibility determination. All information provided in this questionnaire is strictly confidential.

It's important to note that completing this questionnaire does not guarantee eligibility or participation in future trials. The information you provide will be used to keep you informed of updates and potential opportunities, but we cannot ensure that a trial will be available for recruitment.